Fingerprint
Dive into the research topics of 'Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically